Kryon

Kyron.bio is a private French biotech company developing next-generation antibody therapeutics using a proprietary precision glycan engineering platform. The company focuses on controlling glycosylation patterns on therapeutic proteins, particularly antibodies, to improve efficacy, safety, immune engagement, pharmacokinetics, and manufacturability. Kyron.bio operates both as a platform company seeking strategic partnerships and as an emerging therapeutics company with internal preclinical programs. Its technology is aimed primarily at oncology and chronic autoimmune diseases. The company has raised seed financing and non-dilutive grant support and has announced a strategic collaboration with Servier to explore antibody engineering opportunities.